I-Mab Bio
I-Mab Biopharma is a global player in innovative biologics.
I-Mab Bio, founded in August, 2006 and headquartered in Shanghai, is a technology company focusing on innovative biomedicine. The founder is Zang Jingwu. Listed on the NASDAQ on January 17, 2020, the company's major shareholders are I-Mab Biopharma Hong Kong Ltd. Rivals that have direct and indirect competition with I-Mab Bio include Quanto Bio, Yulong Biomedicine, IFM Therapeutics, Melt Pharmaceuticals, etc.
ForLong Biotech Nets Over CNY 100 Mn in Series A
CytoCan Corp. Nets CNY 10 Mn in Seed Round
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
East China medicine "liraglutide" goes to sea
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Hillhouse Q4 position: increased holdings of ideal automobile and Xiaopeng automobile sea, and ideal automobile rushed into the top ten